A PHASE I TRIAL OF TIPIFARNIB WITH RADIATION THERAPY, WITH AND WITHOUT TEMOZOLOMIDE, FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

作者：Nghiemphu Phioanh Leia^*; Wen Patrick Y; Lamborn Kathleen R; Drappatz Jan; Robins H Ian; Fink Karen; Malkin Mark G; Lieberman Frank S; DeAngelis Lisa M; Torres Trejo Alejandro; Chang Susan M; Abrey Lauren; Fine Howard A; Demopoulos Alexis; Lassman Andrew B; Kesari Santosh; Mehta Minesh P; Prados Michael D; Cloughesy Timothy F

来源：International Journal of Radiation Oncology, Biology, Physics, 2011, 81(5): 1422-1427.

DOI：10.1016/j.ijrobp.2010.07.1997

• Tipifarnib
• Newly diagnosed glioblastoma
• Radiation
• Farnesyltransferase inhibitor
• Temozolomide

Purpose: To determine the maximum tolerated dose (MTD) of tipifarnib in combination with conventional radiotherapy for patients with newly diagnosed glioblastoma. The MTD was evaluated in three patient cohorts, stratified based on concurrent use of enzyme-inducing antiepileptic drugs (EIAED) or concurrent treatment with temozolomide (TMZ): Group A: patients not receiving EIAED and not receiving TMZ; Group A-TMZ: patients not receiving EIAED and receiving treatment with TMZ; Group B: any patients receiving EIAED but not TMZ.
Patients and Methods: After diagnostic surgery or biopsy, treatment with tipifarnib started 5 to 9 days before initiating radiotherapy, twice daily, in 4-week cycles using discontinuous dosing (21 out of 28 days), until toxicity or progression. For Group A-TMZ, patients also received TMZ daily during radiotherapy and then standard 5/28 days dosing after radiotherapy. Dose-limiting toxicity (DLT) was determined over the first 10 weeks of therapy for all cohorts.
Results: Fifty-one patients were enrolled for MTD determination: 10 patients in Group A, 21 patients in Group A-TMZ, and 20 patients in Group B. In the Group A and Group A-TMZ cohorts, patients achieved the intended MTD of 300 mg twice daily (bid) with DLTs including rash and fatigue. For Group B, the MTD was determined as 300 mg bid, half the expected dose. The DLTs included rash and one intracranial hemorrhage. Thirteen of the 20 patients evaluated in Group A-TMZ were alive at 1 year.
Conclusion: Tipifarnib is well tolerated at 300 mg bid given discontinuously (21/28 days) in 4-week cycles, concurrently with standard chemo/radiotherapy. A Phase II study should evaluate the efficacy of tipifarnib with radiation and TMZ in patients with newly diagnosed glioblastoma and not receiving EIAED.

• 出版日期2011-12-1